Open access
Sep 2026
Immunotherapy and Targeted Therapy for Metastatic Renal Cell Carcinoma
Lenvatinib plus pembrolizumab provides significant improvements in PFS and objective response compared with sunitinib, while nivolumab plus ipilimumab demonstrates durable long-term survival benefits.
Zhumagazin Zhanabay Derbesinovich
· Oncology, Nuclear Medicine a... · 0 citations